Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | GOT1 | P17174 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MPO | P05164 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.52 |
| ▸ | ACOX1 | Q15067 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalazinone SCHEMBL11770591 | 0.98 | KDM4E (0.53) | NPC1KDM4ERAB9ALMNAALDH1A1 | |
| Phthalazinone SCHEMBL28771488 | 0.86 | EGFR (0.41) | NPC1KDM4ERAB9ALMNAALDH1A1 | |
| Phthalazinone SCHEMBL28826169 | 0.84 | EGFR (0.40) | NPC1KDM4ERAB9ALMNAALDH1A1 | |
| Phthalazinone SCHEMBL27648003 | 0.83 | CYP3A4 (0.50) | NPC1KDM4ERAB9ALMNAALDH1A1 | |
| SCHEMBL14861003 | 0.81 | NPC1 (0.39) | NPC1KDM4ERAB9ALMNAALDH1A1 | |
| Phthalazinone SCHEMBL27786420 | 0.78 | RAB9A (0.45) | NPC1KDM4ERAB9ALMNAALDH1A1 | |
| SCHEMBL30523852 | 0.76 | KDM4E (0.55) | NPC1KDM4ERAB9ALMNAALDH1A1 | |
| SCHEMBL1673296 | 0.76 | KDM4E (0.55) | NPC1KDM4ERAB9ALMNAALDH1A1 | |
| SCHEMBL14283137 | 0.75 | ESR2 (0.46) | KDM4ELMNAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL17295055 | 0.74 | NPC1 (0.53) | NPC1KDM4ERAB9ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368895-A1 | PULMONARY HYPERTENSION TREATING AGENT | THE UNIVERSITY OF TOKYO (JP) | 2016-12-22 | — | — | US | claimed |
| CN-102822172-A | Substituted naphthyridines and their use as syk kinase inhibitors | BOEHRINGER INGELHEIM INT | 2012-12-12 | — | — | CN | claimed |
| EP-2275095-A2 | Neurogenesis by muscarinic receptor modulation | Braincells, Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| US-20030134861-A1 | Transmucosal phosphodiesterase inhibitors for the treatment of erectile dysfunction | DOHERTY PAUL C (US) | 2003-07-17 | — | — | US | claimed |
| US-6548490-B1 | Transmucosally administering to the individual suffering with erectile dysfunction an effective amount of a phosphodiesterase inhibitor selected from type III or type iv phosphodiesterase inhibitor or both | VIVUS, INC. | 2003-04-15 | — | — | US | claimed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| EP-1237577-A2 | TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITOR FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Vivus, Inc. (US) | 2002-09-11 | — | — | EP | claimed |
| US-6403597-B1 | PRETREATMENT SEXUAL INTERCOURSE | VIVUS, INC. | 2002-06-11 | — | — | US | claimed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | claimed |
| US-20020004498-A1 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | DOHERTY PAUL C (US) | 2002-01-10 | — | — | US | claimed |
| WO-2001041807-A2 | TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 2001-06-14 | — | — | WO | claimed |
| US-6156753-A | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-12-05 | — | — | US | claimed |
| US-5585243-A | SEPARATELY INCUBATING HUMAN PLATELETS WITH BLOOD SAMPLE ANDREAGENT DRUG SOLUTION TO FORM COMPLEXES, DETERMINING AMOUNT OF BOUND ANTIBODY | THE BLOOD CENTER OF SOUTHEASTERN WISCONSIN, INC. (US) | 1996-12-17 | — | — | US | claimed |
| WO-1995008116-A1 | METHOD OF DETECTING CYTOPENIA THAT IS MEDIATED BY DRUG-DEPENDENT ANTIBODY BINDING TO BLOOD CELLS | THE BLOOD CENTER OF SOUTHEASTERN WISCONSIN, INC. (US) | 1995-03-23 | — | — | WO | claimed |
| JP-56068609-A | — | — | None | — | — | JP | disclosed |
| JP-59048463-A | — | — | None | — | — | JP | disclosed |
| EP-0086438-A1 | Process and intermediates for preparing 4-hydroxymethyl-1-phthalazone derivatives | Nippon Kayaku Kabushiki Kaisha (JP) | 1983-08-24 | — | — | EP | disclosed |
| JP-S5668609-A | PHTHALAZINOL PREPARATION | NIPPON KAYAKU CO LTD | 1981-06-09 | — | — | JP | disclosed |
| US-4182876-A | ANTAGONIST FOR THROMBOXANE A2, USED IN TREATMENT OF CEREBRAL APOPLEXY AND MYOCARDIAL INFARCTION | MASAYUKI ISHIKAWA (JP) | 1980-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134861-A1 | Transmucosal phosphodiesterase inhibitors for the treatment of erectile dysfunction | PDE5A, PDE3A, PDE3B | NPC1 2430/4885KDM4E 721/4885RAB9A 1052/4885 |
| US-20020004498-A1 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | PDE3A, PDE5A, PDE3B | NPC1 2023/4885KDM4E 2302/4885RAB9A 1257/4885 |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | PDE5A, PDE3B, PDE3A | NPC1 4750/4885KDM4E 123/4885RAB9A 2052/4885 |
| US-20160368895-A1 | PULMONARY HYPERTENSION TREATING AGENT | PTGIR, AGTR1, PTGER1 | NPC1 4018/4885KDM4E 4284/4885RAB9A 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.